Literature DB >> 19282697

Recurrent Escherichia coli bloodstream infections: epidemiology and risk factors.

Marta Sanz-García1, Ana Fernández-Cruz, Marta Rodríguez-Créixems, Emilia Cercenado, Mercedes Marin, Patricia Muñoz, Emilio Bouza.   

Abstract

Patients with recurrent episodes of Escherichia coli bloodstream infection (REC-BSI) have been described previously only in small studies. We report on the incidence, clinical significance, and predisposing conditions of REC-BSI in a general hospital from 1992 to 2005. All patients with E. coli bloodstream infection (EC-BSI) were retrieved from our database. We defined recurrent episodes as those occurring at least 1 month apart after a clinical response (cases). To study risk factors for REC-BSI, we randomly selected a third of the REC-BSI cases and a similar number of controls (patients with a single EC-BSI). Available E. coli isolates from initial and recurrent episodes were typed using repetitive-extragenic-palindromic-sequences to distinguish between relapse and reinfection. During the study period there were 4287 episodes of EC-BSI in 3970 patients; of these, 251 (6.3%) patients had 568 episodes of recurrence (13.3%). We selected 81 cases and 81 controls for study. The underlying conditions of patients with REC-BSI included immunosuppression (33%), urinary (24%) or biliary obstruction (16%), chronic liver disease (16%), presence of a central venous catheter (8%), and miscellaneous entities (3%). Male sex, presence of hematologic malignancy, inadequate antibiotic treatment, and an extraurinary source of the BSI were independent risk factors for recurrence in the multivariate analysis. Molecular typing performed in 88 infections from 44 patients showed that 47% of REC-BSI were relapses rather than reinfections. Recurrence of E. coli BSI is not an uncommon phenomenon and includes relapses (47%) and reinfections (53%). Recurrence should suggest not only the presence of urinary or biliary obstruction, but also the presence of immunosuppression.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19282697     DOI: 10.1097/MD.0b013e31819dd0cf

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.889


  4 in total

1.  Enhanced Survival of Rifampin- and Streptomycin-Resistant Escherichia coli Inside Macrophages.

Authors:  Paulo Durão; Daniela Gülereşi; João Proença; Isabel Gordo
Journal:  Antimicrob Agents Chemother       Date:  2016-06-20       Impact factor: 5.191

2.  Relapsing sepsis episodes of Escherichia coli with CTX-M ESBL or derepressed ampC genes in a patient with chronic autoimmune pancreatitis complicated by IgG4 hypergammaglobulinaemia.

Authors:  T Tuuminen; M Österblad; S Hämäläinen; R Sironen
Journal:  New Microbes New Infect       Date:  2015-11-30

3.  The genetic basis of Escherichia coli pathoadaptation to macrophages.

Authors:  Migla Miskinyte; Ana Sousa; Ricardo S Ramiro; Jorge A Moura de Sousa; Jerzy Kotlinowski; Iris Caramalho; Sara Magalhães; Miguel P Soares; Isabel Gordo
Journal:  PLoS Pathog       Date:  2013-12-12       Impact factor: 6.823

4.  Clinical and Microbiological Characteristics of Recurrent Escherichia coli Bacteremia.

Authors:  Tatsuya Kobayashi; Mahoko Ikeda; Yuta Okada; Yoshimi Higurashi; Shu Okugawa; Kyoji Moriya
Journal:  Microbiol Spectr       Date:  2021-12-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.